Allergy

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

Altman spoke in a recent interview about the main takeaways from his AAAAI presentation, during which he discussed systems biology research into allergic diseases.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

According to data from the AAAAI 2023 Annual Meeting, individuals with food allergies face numerous barriers when managing their condition while flying, with only 15% receiving epinephrine.

In an interview regarding his AAAAI poster session, Dellon described a sub-analysis of new phase 3 trial data on dupilumab for eosinophilic esophagitis patients.

"We are looking at trying to satisfy a truly unmet medical need," Dr. David Dworaczyk says about the development of a new epinephrine nasal spray for anaphylaxis.

Dr. David Dworaczyk explains phase 3 data showing a single intranasal dose of epinephrine produced a higher and more prolonged plasma curve compared to an intramuscular 0.3 mg autoinjector.

Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

A study from the AAAAI 2023 Annual Meeting reveals racial and ethnic disparities in the management of severe asthma and highlights the need for interventions to improve care escalation for Black and Hispanic/Latino patients.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

The house dust mite allergen extract was approved by the FDA for treating adolescents with immunotherapy.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.

Allergic contact dermatitis burden many people, but it is important for patients to know why and how they may limit their risk.

An interview segment with Peter Young featuring a description of the response to the research into personal care product allergens.

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.